Key regions: Japan, India, Italy, Brazil, South Korea
South Africa is a country with a high prevalence of hypertension, making the Anti-Hypertensive Drugs market a crucial part of the pharmaceutical industry.
Customer preferences: The South African population, particularly those over the age of 50, are more likely to suffer from hypertension, which makes them the primary target market for Anti-Hypertensive Drugs. Patients with hypertension usually require lifelong treatment, which makes drug adherence an essential factor in the market. Patients prefer drugs that are affordable, effective, and have minimal side effects.
Trends in the market: The Anti-Hypertensive Drugs market in South Africa has been growing steadily in recent years, driven by an increase in the prevalence of hypertension and the aging population. The market is also experiencing a shift towards combination therapies, which are more effective in controlling hypertension. The government's implementation of National Health Insurance (NHI) is expected to increase access to healthcare and, therefore, increase demand for Anti-Hypertensive Drugs. The market is also experiencing an increase in the use of generic drugs, which are more affordable than branded drugs.
Local special circumstances: South Africa has a high prevalence of hypertension, with approximately 6 million people suffering from the condition. The country's healthcare system is divided into the public and private sectors, with the majority of the population relying on the public sector for healthcare. The government has implemented various programs to increase awareness of hypertension and encourage early detection and treatment. The private sector caters to the middle and upper-class population and offers more specialized care.
Underlying macroeconomic factors: The South African economy has been struggling in recent years, with high unemployment rates and low economic growth. The pharmaceutical industry has been affected by the weak economy, with consumers opting for more affordable drugs. The government's implementation of NHI is expected to increase access to healthcare, which will increase demand for Anti-Hypertensive Drugs. The market is also affected by the country's regulatory environment, which has become more stringent in recent years. This has resulted in longer approval times for new drugs, which has slowed down innovation in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
